Open AccessEffective use of hydroxyurea for sickle cell anemia in low-resource countries
Author(s) -
Alexandra PowerHays,
Russell E. Ware
Publication year - 2020
Publication title -
current opinion in hematology/current opinion in hematology, with evaluated medline
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 97
eISSN - 1080-8213
pISSN - 1065-6251
DOI - 10.1097/moh.0000000000000582
Subject(s) - medicine , clinical trial , disease , anemia , hematology , health care , intensive care medicine , sickle cell anemia , family medicine , hydroxycarbamide , business , economic growth , economics
Over the past several decades, hydroxyurea has emerged as a well tolerated and potent disease-modifying therapy for children and adults with sickle cell anemia (SCA). Strong, evidence-based recommendations from the National Institutes of Health, American Society of Hematology, and British Society of Haematology document that hydroxyurea is now standard of care treatment for SCA. In low-resource settings, however, hydroxyurea is rarely utilized due to lack of availability, inadequate treatment guidance, and excessive costs.